Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 12/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | CCR1 | P32246 | 1/20 | 0.36 |
| ▸ | CCR3 | P51677 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21071557 | 1.00 | ESR1 (0.39) | ESR1NAMPTHTR2AHTR7ROCK1 | |
| SCHEMBL21071559 | 1.00 | ESR1 (0.39) | ESR1NAMPTHTR2AHTR7ROCK1 | |
| SCHEMBL21071864 | 0.92 | ESR1 (0.39) | ESR1NAMPTHTR2AHTR7ROCK1 | |
| SCHEMBL19839294 | 0.92 | ESR1 (0.39) | ESR1NAMPTHTR2AHTR7ROCK1 | |
| SCHEMBL19839292 | 0.92 | ESR1 (0.39) | ESR1NAMPTHTR2AHTR7ROCK1 | |
| SCHEMBL19852326 | 0.85 | NAMPT (0.47) | NAMPTHTR2AHTR7 | |
| SCHEMBL19852180 | 0.80 | HTR7 (0.51) | HTR2AHTR7CCR3 | |
| SCHEMBL21071810 | 0.79 | CYP19A1 (0.39) | HTR2AHTR7CCR1CCR3 | |
| SCHEMBL21071466 | 0.79 | HTR7 (0.44) | ESR1HTR2AHTR7CCR1CCR3 | |
| SCHEMBL21071464 | 0.79 | HTR7 (0.44) | ESR1HTR2AHTR7CCR1CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SCN2A, HTR2A, HTR2C | ESR1 4271/4885NAMPT 2423/4885HTR2A 2/4885 |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SCN2A, HTR2A, HTR2C | ESR1 4271/4885NAMPT 2423/4885HTR2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.